RATIONALE 301, 2024 NCT03412773
Tislelizumab (n=342) vs. sorafenib (n=332)
randomized controlled trial
tislelizumab
200 mg IV once every 3 weeks
sorafenib
400 mg twice daily (BID) po
mHCC - 1st line (L1)
Geographic region : asia (excluding Japan) 63%; Japan 11%; rest of world 26%
open label
117 centers, 11 countries